May 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.57 USD | +2.63% | +1.92% | -17.03% |
01:37pm | ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial | MT |
Jun. 07 | Geron shares surge after U.S. FDA approves blood disorder drug | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.03% | 84.08B | |
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves expanded use of Bristol's cancer cell therapy